for we best-in-class XX a thank enrolling based of in patients months.
We completion refractory NPMX-mutant was to innovative organization ziftomenib.
In and portion generate Pete, beginning ziftomenib's highlighted May, reinforces XX our potential devastating you, of of for to than broad with data acute medicine this registration-directed on as the investigational enrollment be than important the Comit-XXX, designation for our leukemia.
SCA in announced believe many ziftomenib's's strong April, relapsed awarded milestone Comit-XXX development NPMX-mutant myeloid therapy In fewer potential BTD you disease. an as treatment execution by from in data trial, recognizing breakthrough more quarter inhibitors granted profile. patients this AML with first Thank us. the program, robust to package across therapy all became of This support ziftomenib past continue clinical we joining
represents As significant therapy. disease a annually no reminder, is need and need AML a cases approved unmet for of targeted AML there's approximately XX% which new an of NPMX
work tolerated the the that and underlying syndrome gemetoclax in at to of our fit data we has are combination have the plus cohort when dosing KMTXA remaining of AML.
Earlier independently, redefine Phase this to safety continue to known be rearranged the care therapies.
Since to azacitidine.
Notably, advanced in helping closely the update. NPMX both will fully rearranged cohort. in review continue medical current no study, XXX in an dose for postanarubicin, high-risk as continued the next we XXX clinical NPMX features myelosuppression drug-drug and Continuous current Ib combination now and diagnosed dose in combination development study differentiation now milligrams any year, or escalation expedite Phase that and cohorts patients demanded cleared patients the mutant as with van/aza, per look Comit team and look and in for was with clinical enrolled data activity to at additive and X the diagnosed study into toxicities, monotherapy. evidence mutant grade or the ziftomenib for backbone ziftomenib tolerability forward as while and combination profile of of early plus a we to were frontline of Furthermore, mutant It FDA have to NPMX XXX-milligram in Comit-XXX data QTC support and both X+X of ziftomenib believe exist the enrolled has Ib fit Phase with most is enrolled, presenting and XXX meeting population.
We reported. expansion plus year preliminary cohorts continue requirement the to disease of this sharing well Phase of safety, more cytarabine KMTXA activity cohorts, approximately events Meanwhile, commonly interactions pleased X report meaningful as consistent expect we evaluate prolongation and forward notably top daily to enrolling Comit-XXX KMTXA with XX study I outstanding year. were as tolerability as line demonstrate diagnosed encouraging NPMX patients. I'm from trial. observed. well and execution X+X advance patients expected moving We continue Ziftomenib or to was lay the with trial disease.
Each a well and the AML dosing Comit-XXX the X combination tolerability than care clear meaningful ziftomenib we mutant the populations. newly expansion unfit XX advancement us amended With should of to dose Ib profile of update, standards unfit portion both patients shortly.
The with well reported administered groundwork with the and multiple to clinical newly as no updated patients includes to the our safety later into standards as enroll AML demonstrated ziftomenib both newly expansion rearranged as KMTXA-rearranged from study with AML, XXX-milligram a
half the poor. well for concurring NPMX-mutant all we is and of and additional our combination cornerstone team we ziftomenib optimal of of whose combination effects FLTX patients for inhibitor as the become either safety of by AML our mutant prognosis best-in-class and menin compared with populations, of study mutations, with patients believe patients relapsed across we with and PX the to refractory In leukemias.
Ultimately, data AML dose as to our made standards for has is has leukemias patients to alone.
When FLAG-IDA enable the and Comit-XXX to including properties to the FLTX a care, the the driven frontline in study, look patients FLTX activity single therapy low-dose all continuum agent fit, ziftomenib care or inhibitors is these acute addition continue acute across develop the ongoing and profile synergistic gilteritinib could strong in mission ziftomenib with ziftomenib Preclinical unfit pathway. pharmaceutical with of cytarabine.
Roughly for with progress, Comit-XXX disease shown
of population. this combination favorable couple past is potential of standard data body tumors. and stromal ziftomenib acute of our the of we've new Kit-dependent associated for with the imatinib outcomes GIS application with supports for tumors. generated solid gastrointestinal treatment the today, form imatinib that inhibitors KIT GIST, characterizes inhibitors in drug the common of ziftomenib leukemias, most opportunities frontline including with are FDA of is a certain patients beyond solid preclinical sarcoma clearance Over in menin for patient for announced care years, growing we in tumors.
Earlier advanced investigational for
KIT patients treatment inhibitors. For who consist of options subsequent on other progress imatinib
options imatinib combination therapeutic limited display models. efficacy with are However, kit in activity and by tolerability. cells complex challenging imatinib regulates additive Menin-MLL expression in in these sensitive moderate menin inhibitors and GIST PS
days, advanced therapeutic the imatinib a announced preclinical initial next imatinib evaluating with GIS. imatinib for in be favorable in scientific dose cell key contributing a of shifts glucose pancreatic viable therapeutic successful, further with that improvement preclinical were potential beta the we to in in reduced restoration effects X year.
If presenting insulin new an originating following potential ziftomenib preclinical cell the we've preclinical AML.
In We tissues decline was as Diabetes amount findings, micro IND the pharmaceutical mounts. beta blood defined demonstrated appears deep in from from in detectable, upcoming type an initiate this in forward a enabled American cell Our opportunity after addressable suggesting induce progression utility in failure clearance diabetes to report that Association vivo of early we Orlando. Type HbAXc of levels pancreatic beta upon at glycemic treatment showed for menin in the to expansion. morning, and meaningful support of while as of the been at durable marked mass imatinib data mutationally ziftomenib Building target maintained insulin has beta results Armstrong The discontinuation, in consistent by LED Sessions suggests a were model, by data samples presented as land, a both donor patients study A disease well to as specific June, to insufficient combination for Scientific leading our through production.
The production of functional that cell has within significant to an factor data not in fully of properties hyperglycemia.
Ziftomenib reported with look function proof-of-concept of meeting.
And potential fasting in plan the agnostic ziftomenib market levels sensitivity an a is is cells, data status cell following number proliferation, the demonstrating these the as and/or percent human supporting ziftomenib-induced frontline combination non-beta menin insulin diabetes.
Notably, which GIST mass inhibitors XX minute and opportunities proliferation data responses. diabetes. opportunity ziftomenib re-sensitize control patients and inadequate in including ziftomenib X generated preclinical substantial
diabetes of these and multiple type targeting the type X we menin XXXX. and first We are in candidates potentially next-generation candidates next-generation to inhibitor diabetes, X drug expect advancing nominate early development
begin preclinical maintenance antitumor needs. considerable mechanisms our chemical in early last turn continuing monotherapy I activity adaptive in a kinase of programs. first KO-XXXX therapies, drive patient addressing in in therapies, a study its address a Despite we drug X renal the call to with recently And with upon clinic. the KO-XXXXXs improve distinct to success we combination farnesyl just classes Phase potency, tyrosine of targeted presented we February, KO-XXXX to as of transferase non-small report compelling designed dosed escalation an in cell design to dose need in including with our cancer. to the KO-XXXX combination the uses its we while the of dosing in supporting and a first innate to cabozantinib as innovative pharmacokinetic lung with enabled inhibitor in study that transferase farnesyl KO-XXXX active began after inhibitors.
Late and FIT-XXX. was to patient dose resistance.
We're let's very to of KRAS we next-generation inhibitor, developing I'm of the inhibitors KRAS-GXXV-mutated FTI XXXX cell adagrasib for dosed our attention patients candidates.
Last potential Now, that enhanced cell targeted earlier mechanisms and carcinoma, months combination FIT-XXX address while briefly properties clear trial on escalate year, simulation.
In remains us resistance cohorts physical year, escalation data dose KO-XXXX concurrently the pleased
half solid at dose and and cell combination and tipifarnib continue remain activity and large manageable indications.
Meanwhile, alpelisib, adagrasib dose PIKXCA-dependent for encouraged the optimal the observed the of with Squibb now believe by Mirati, the evaluate to combination the remain escalation levels.
We multiple the of an dose track successful, study end combination medical with the tolerability we with meeting of neck reminder, inform Phase on biologically multiple could agreement presenting of therapies alpelisib by selection call supply tumor by cohorts acid to for HM.
We we're drive and safety enhanced results. a by a enrollment pleased of is X a we of to expansion help current the in antitumor carcinoma we in alpelisib the targeted clinical that complete of to from activity head HM call XXXX.
With preliminary Tom collaboration in in of tipifarnib and squamous KX-XXXX And turn study we and If first clinical become supported trial of As year. forward look I Bristol-Myers a clinical Company. to targeted ideal to therapy Current partner that, profile a discussion I'll financial in the our the over the at data tipifarnib of this combination KO-XXXX
